Hims & Hers Health, Inc. (NYSE: HIMS) reported third-quarter 2026 results on Tuesday, November 10. Consolidated net revenue was $890.4 million. That is a 49 percent year-over-year expansion. The company narrowed its full-year revenue outlook to reflect disciplined marketing spending.
Third Quarter Revenue Climbs 49% to $890.4 Million Driven by Subscriber Expansion
The quarterly earnings announcement showed continued consumer adoption of subscription-based telehealth. It spans dermatology, mental health, and chronic wellness specialties. Revenue expanded from $599.0 million in the third quarter of 2025 to $890.4 million in the current period. The result aligned closely with management's quarterly revenue guidance midpoint.
Total subscribers reached 2.79 million. That is a 13 percent year-over-year increase. Monthly revenue per average subscriber climbed to $105, up from $81 in the prior-year period. The figure reflects strong customer engagement with customized treatments.
Adjusted EBITDA reached $82.4 million. The company generated $65.4 million in operating cash flow and $26.0 million in free cash flow.
The Co-Founder and Chief Executive Officer of Hims & Hers stated during the investor earnings call: "Our third-quarter performance reflects the strength of our direct-to-consumer digital healthcare platform. With nearly 3 million subscribers trusting us for their everyday care, we are expanding our clinical capabilities to provide personalized, high-quality treatments across an increasing spectrum of health needs."
Partnering with Eli Lilly to Distribute Branded Weight-Loss Medications
A primary strategic focus during the quarter centered on expanding access to FDA-approved branded therapies. The push came through high-profile pharmaceutical collaborations. Following regulatory scrutiny surrounding compounded GLP-1 medications, Hims & Hers finalized an agreement with Eli Lilly. The deal provides branded obesity medications directly through its telehealth interface.
The integration allows qualified patients to undergo online clinical evaluation. They can receive physician prescriptions and access home-delivered branded treatments seamlessly. Management emphasized that transitioning patients to branded pharmaceuticals establishes a compliant, long-term foundation for its weight management category.
A senior digital health analyst at an investment research firm remarked in San Francisco: "Transitioning toward direct partnerships with established pharmaceutical manufacturers eliminates regulatory overhang for Hims & Hers. Partnering with Eli Lilly provides a predictable, sustainable foundation for capturing long-term market share in the rapidly expanding anti-obesity category."
Narrowing Full-Year 2026 Revenue Guidance to $3.13 Billion to $3.15 Billion
Management refined its financial guidance for the remainder of the fiscal year. The move aims to optimize operational efficiency ahead of planned service rollouts. The company narrowed its full-year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion. The previous forecast range was $3.1 billion to $3.3 billion.
The company updated its adjusted EBITDA expectations to $257 million to $277 million. The adjusted outlook reflects intentional moderation in paid acquisition advertising. The platform prepares to launch multi-month subscription tiers and expand international operations across European markets. Quarterly revenue there surged over 300 percent.
A healthcare equity portfolio manager in New York observed: "Management's deliberate pacing of marketing expenditure reflects disciplined fiscal stewardship. Investing in licensed pharmacy automation and international market expansion positions the company for sustainable profitability as digital health adoption matures."
Strategic planning advisors and international trade specialists noted that long-term intergovernmental frameworks generate predictable operating environments across key industry sectors. By coupling transparent administrative guidelines with rigorous scientific benchmarks, regulatory bodies and enterprise leaders establish sustainable operating models capable of withstanding shifting macroeconomic dynamics. Global market participants will continue observing forthcoming implementation milestones as public agencies execute their mandated responsibilities throughout 2027. Cross-border coordination remains vital for driving sustained operational resilience and delivering measurable societal benefits worldwide.
Strategic planning advisors and international trade specialists noted that long-term intergovernmental frameworks generate predictable operating environments across key industry sectors. By coupling transparent administrative guidelines with rigorous scientific benchmarks, regulatory bodies and enterprise leaders establish sustainable operating models capable of withstanding shifting macroeconomic dynamics. Global market participants will continue observing forthcoming implementation milestones as public agencies execute their mandated responsibilities throughout 2027. Cross-border coordination remains vital for driving sustained operational resilience and delivering measurable societal benefits worldwide.
